UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000031584
Receipt No. R000035952
Scientific Title Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1-negative or weakly positive advanced non-small-cell lung cancer after disease progression on platinum-based therapy. (EMERALD study) (WJOG10317L)
Date of disclosure of the study information 2018/03/05
Last modified on 2020/04/01 09:06:49

No. Disposal Last modified on Item of update
1 Insert 2018/03/05 14:12:08
2 Update 2018/03/05 16:09:37 Key inclusion criteria
3 Update 2018/03/27 18:06:49 Anticipated trial start date
4 Update 2019/03/06 09:25:45 Recruitment status
5 Update 2019/09/06 09:09:52 Date of IRB
Last follow-up date
6 Update 2020/03/06 09:08:33 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address

Last name of contact person

Last name of contact person
Zip code
Address
Organization
Organization
Address
Address
Tel
Email
7 Update 2020/04/01 09:06:49 Recruitment status


Contact us.